Plasma α-synuclein is decreased in subjects with Parkinson's disease

被引:124
作者
Li, Qiao-Xin [1 ]
Mok, Su San
Laughton, Katrina M.
McLean, Catriona A.
Cappai, Roberto
Masters, Colin L.
Culvenor, Janetta G.
Horne, Malcolm K.
机构
[1] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia
[2] Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia
[3] Univ Melbourne, Ctr Neurosci, Parkville, Vic 3010, Australia
[4] Alfred Hosp, Dept Pathol Anat, Melbourne, Vic 3181, Australia
[5] Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3010, Australia
基金
英国医学研究理事会;
关键词
Parkinson's disease; alpha-synuclein; plasma;
D O I
10.1016/j.expneurol.2006.12.006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
alpha-Synuclein (alpha SN) is implicated in Parkinson's disease (PD) and is the major component of Lewy bodies (LBs). Although alpha SN is mainly expressed in neuronal cells and exists as cytoplasmic protein, it haas been found in body fluids including cerebrospinal fluid and blood. This study explored plasma alpha SN as a diagnostic marker for PD. Western blot analysis was used to characterize plasma alpha SN compared to brain alpha SN. Plasma alpha SN of 16 kDa migrates with the same mobility as its brain counterpart and recombinant alpha SN on denatured polyacrylamide gels and reacted with three different antibodies against the C-terminal and NAC regions of the alpha SN protein. The alpha SN levels in plasma from PD subjects are significantly lower than that in age-matched controls (p = 0.001), and the alpha SN levels in patients with early-onset PD are lower than that in both late-onset PD and controls. This initial study indicates that measurement of alpha SN in plasma can provide support for a clinical diagnosis of Parkinson's disease and warrants further study in a larger population. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:583 / 588
页数:6
相关论文
共 40 条
  • [1] Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
    Abeliovich, A
    Schmitz, Y
    Fariñas, I
    Choi-Lundberg, D
    Ho, WH
    Castillo, PE
    Shinsky, N
    Verdugo, JMG
    Armanini, M
    Ryan, A
    Hynes, M
    Phillips, H
    Sulzer, D
    Rosenthal, A
    [J]. NEURON, 2000, 25 (01) : 239 - 252
  • [2] Baba M, 1998, AM J PATHOL, V152, P879
  • [3] CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry
    Blennow, K
    Vanmechelen, E
    [J]. BRAIN RESEARCH BULLETIN, 2003, 61 (03) : 235 - 242
  • [4] Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects
    Borghi, R
    Marchese, R
    Negro, A
    Marinelli, L
    Forloni, G
    Zaccheo, D
    Abbruzzese, G
    Tabaton, M
    [J]. NEUROSCIENCE LETTERS, 2000, 287 (01) : 65 - 67
  • [5] Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication
    Buhmann, C
    Arlt, S
    Kontush, A
    Möller-Bertram, T
    Sperber, S
    Oechsner, M
    Stuerenburg, HJ
    Beisiegel, U
    [J]. NEUROBIOLOGY OF DISEASE, 2004, 15 (01) : 160 - 170
  • [6] Accumulation of insoluble α-synuclein in dementia with Lewy bodies
    Campbell, BCV
    Li, QX
    Culvenor, JG
    Jäkälä, P
    Cappai, R
    Beyreuther, K
    Masters, CL
    McLean, CA
    [J]. NEUROBIOLOGY OF DISEASE, 2000, 7 (03) : 192 - 200
  • [7] The solubility of α-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease
    Campbell, BCV
    McLean, CA
    Culvenor, JG
    Gai, WP
    Blumbergs, PC
    Jäkälä, P
    Beyreuther, K
    Masters, CL
    Li, QX
    [J]. JOURNAL OF NEUROCHEMISTRY, 2001, 76 (01) : 87 - 96
  • [8] Dopamine promotes α-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway
    Cappai, R
    Leck, SL
    Tew, DJ
    Williamson, NA
    Smith, DP
    Galatis, D
    Sharples, RA
    Curtain, CC
    Ali, FE
    Cherny, RA
    Culvenor, JG
    Bottomley, SP
    Masters, CL
    Barnham, KJ
    Hill, AF
    [J]. FASEB JOURNAL, 2005, 19 (08) : 1377 - +
  • [9] Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO
  • [10] 2-E